Sort   by:  
 Page size 
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis (FIA-MS) (C.saccharolyticum;E.coli;L.plantarum;L.lactis;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1791 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (E.coli;C.saccharolyticum;S.salivarius;E.rectale;L.plantarum;L.lactis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1627 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (B.animalis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1264 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (L.saccharolytica;Standards assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS2885 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: duloxetine accumulation at different concentrations (L.saccharolytica;E.coli assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1319 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1792 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis for resting cells (B.uniformis;C.saccharolyticum assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1757 | MetaboLights
ProteomicsNCI60 proteome by PCT-SWATH - Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines
We obtained quantitative analysis of the NCI-60 cell panels using pressure cycling technology (PCT) and SWATH-MS. Each cell was analyzed in duplicate. The data were analyzed using a cell line SWATH assay library and OpenSWATH, followed by SWATH-expert refinement.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2020-07-29 | MSV000085848 | MassIVE
UnknownDominant negative variants in IKZF2 cause ICHAD syndrome, a new disorder characterised by immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay.
Not available
S-EPMC11206234 | biostudies-literature
UnknownSARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.
Not available
S-EPMC8132231 | biostudies-literature
Sort   by:  
 Page size